Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Arrowstreet Capital Limited Partnership Boosts Stake in Abbott ...

AI-generated analysis

📈 Arrowstreet Capital boosted its Abbott Laboratories stake by 217.0% in Q1, adding 3.78 million shares to a total holding of 5.52 million shares worth $566.97 million.

🏦 Multiple institutional investors including Caxton Associates ($290k), Dickmeyer Boyce ($829k), Ascension Capital ($459k), and B&D White Capital ($2.41M) initiated new positions in the first quarter.

📉 Goldman Sachs lowered its price target to $113 with a 'buy' rating, while Bank of America cut its target to $102, reflecting cautious near-term outlooks from major banks.

📈 UBS Group reduced its price target to $135 but maintained a 'buy' rating, and Leerink Partners lowered its target to $106 with a 'market perform' rating.

💰 Abbott Laboratories reported Q2 EPS of $1.31, beating the consensus estimate of $1.28, while revenue grew 13.0% year-over-year to $12.51 billion.

📊 The company achieved a return on equity of 17.65% and a net margin of 11.65%, demonstrating solid profitability despite the slight miss in revenue expectations.

🔮 Abbott Laboratories issued Q3 2026 EPS guidance of $1.38-$1.46 and full-year 2026 guidance of $5.45-$5.60, with analysts expecting $5.51 EPS for the current fiscal year.

💵 The firm declared a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record as of July 15th, representing a 2.5% annualized yield.

👔 Director Daniel J. Starks purchased 10,000 shares at an average price of $92.65, increasing his personal ownership by 0.15% to a total value of approximately $625.49 million.

📉 The stock trades at a P/E ratio of 32.64 with a market capitalization of $175.70 billion, currently trading above its 50-day moving average but below its 200-day average.

Bullish Signals
  • Arrowstreet Capital increased its position by 217.0% in Q1, signaling strong institutional confidence in the company's long-term value.
  • Abbott Laboratories beat quarterly earnings estimates with $1.31 EPS compared to the consensus of $1.28.
  • Revenue grew 13.0% year-over-year to $12.51 billion, indicating robust top-line growth despite a slight miss in absolute revenue expectations.
  • The company maintains a healthy return on equity of 17.65% and a net margin of 11.65%, reflecting efficient operations.
  • Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $118.61, supported by multiple 'Buy' and 'Strong Buy' ratings.
  • The company has a strong balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
  • Abbott Laboratories offers an attractive dividend yield of 2.5% with a payout ratio of 81.55%, providing income to investors.
Risk Factors
  • Several major analysts, including Goldman Sachs, Bank of America, and UBS, recently lowered their price targets on Abbott Laboratories stock.
  • Revenue of $12.51 billion missed analyst expectations of $12.52 billion, indicating a slight slowdown in top-line growth.
  • The stock is trading below its 200-day simple moving average of $101.32, suggesting some short-term weakness or consolidation.
  • Analyst consensus for full-year 2026 EPS of $5.51 is slightly higher than the company's own guidance range of $5.45-$5.60, implying potential pressure to meet high expectations.
Full Analysis
Arrowstreet Capital Limited Partnership significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 217.0% in the first quarter, purchasing an additional 3.78 million shares to hold a total position of 5.52 million shares valued at $566.97 million. Several other institutional investors, including Caxton Associates, Dickmeyer Boyce, Ascension Capital, Forefront Analytics, and B&D White Capital, also established or increased their positions in the healthcare giant during the same period. Analyst sentiment remains mixed but generally positive regarding Abbott's long-term prospects despite recent price target reductions. Major firms like Goldman Sachs, Barclays, Bank of America, UBS, and Leerink Partners lowered their price targets to $113, $143, $102, $135, and $106 respectively in April and June. However, the consensus rating remains a 'Moderate Buy' with an average price target of $118.61, supported by three Strong Buy ratings and nineteen Buy ratings from analysts. Abbott Laboratories reported strong financial performance for the quarter ended July 16th, beating earnings estimates with $1.31 EPS against a consensus of $1.28. Revenue reached $12.51 billion, slightly missing expectations at $12.52 billion but growing 13.0% year-over-year. The company provided guidance for Q3 2026 EPS between $1.38 and $1.46 and full-year 2026 EPS between $5.45 and $5.60, while also announcing a quarterly dividend of $0.63 payable on August 17th.